Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers

DOI: 10.20524/aog.2019.0377

Keywords: Biosimilar, CT-P13, Crohn’s disease, infliximab, ulcerative colitis

Full-Text   Cite this paper   Add to My Lib

Abstract:

The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology centers

Full-Text